Neuropsychiatric Inventory

Neuropsychiatric Inventory

A neurological testing instrument used to assess patients with Alzheimer’s disease, which assesses 12 neuropsychiatric disturbances commonly seen in dementia;
• Aberrant motor behaviour;
• Agitation;
• Anxiety
• Apathy;
• Delusions;
• Disinhibition;
• Dysphoria
• Eating disturbances;
• Euphoria;
• Hallucinations;
• Irritability;
• Night-time behaviour disturbances.
References in periodicals archive ?
After 10 weeks, the 93 patients on dextromethorphan plus quinidine had their average neuropsychiatric inventory domain score for agitation and aggression cut roughly in half, compared with baseline; among 66 control patients, the drop in average score was about 25%, a statistically significant difference for the study's primary endpoint, Dr.
(16) Neuropsychiatric symptoms were assessed using the Chinese version of the Neuropsychiatric Inventory (NPI) to define the presence and severity of neuropsychiatric symptoms.
According to the company, the main efficacy measure is the Neuropsychiatric Inventory or NPI.
The mean composite score on the Neuropsychiatric Inventory improved by 19.6% in the ginkgo group and did not change in the placebo group (p < 0.001 for the difference in the change between groups).
The combination not only significantly improved total scores on the Neuropsychiatric Inventory (NPI), but individual scores on agitation/ aggression, elation/euphoria, emotional lability, and appetite, Suzanne Hendrix, Ph.D., reported in two posters presented at the annual meeting of the American Association for Geriatric Psychiatry.
The combination not only significantly improved total scores on the Neuropsychiatric Inventory (NPI), but individual scores on agitation/aggression, elation/euphoria, emotional lability, and appetite, Suzanne Hendrix, Ph.D., reported in two posters presented at the annual meeting of the American Association for Geriatric Psychiatry.
Neuropsychiatric symptoms were identified using the Chinese version of Neuropsychiatric Inventory (NPI) to define the presence and severity of neuropsychiatric symptoms.
Memantine exerted "no significant effects" whether patients with mild AD were assessed using the Alzheimer Disease Assessment Scale-Cognitive Sub-scale (ADAS-cog), the Clinician's Interview-Based Impression of Change Plus Caregiver's Input (CIBIC-plus), the Alzheimer Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, or the Neuropsychiatric Inventory (NPI).
Measures used for caregivers included the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) to measure participant function, the QoL-AD to measure participant quality of life, the Neuropsychiatric Inventory Questionnaire to measure the frequency and severity of dementia-related symptoms (NPI-FS), as well as the NPI Caregiver Distress Scale (NPI-D).
Secondary endpoints included the change from baseline on a 13-item version of the ADAS-Cog, the Mini Mental State Examination, the Clinician's Interview-Based Impression of Change, the Neuropsychiatric Inventory, and the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL).
Adverse events were assessed at baseline and at weeks 3, 6, and 12 by self-report, as well as by the Epworth Sleepiness Scale, the Neuropsychiatric Inventory, the Barratt Impulsiveness Scale, and ankle circumference.
Measures used for caregivers included the Alzheimer's Disease Cooperative Study--Activities of Daily Living Inventory (ADCS-ADL) to measure participant function, the QoL-AD to measure participant quality of life, the Neuropsychiatric Inventory Questionnaire to measure the frequency and severity of dementia-related symptoms (NPI-FS), as well as the NPI Caregiver Distress Scale (NPI-D).